Literature DB >> 24395091

Higher circulating levels of chemokine CCL20 in patients with multiple sclerosis: evaluation of the influences of chemokine gene polymorphism, gender, treatment and disease pattern.

A Jafarzadeh1, S Bagherzadeh, H A Ebrahimi, H Hajghani, M R Bazrafshani, A Khosravimashizi, M Nemati, F Gadari, A Sabahi, F Iranmanesh, M M Mohammadi, H Daneshvar.   

Abstract

Chemokines play an important role in the autoimmune diseases. The aim of this study was to investigate the levels of CCL20 and a polymorphism [-786C > T (rs6749704)] in the chemokine gene in patients with multiple sclerosis (MS). The blood samples were collected from 135 MS patients and 135 healthy subjects as a control group. The patients have relapsing-remitting (RRMS; n = 65), primary progressive (PPMS; n = 47), secondary progressive (SPMS; n = 35) or progressive relapsing (PRMS; n = 14) patterns. The serum levels of CCL20 were measured by ELISA. The DNA was analyzed for CCL20 polymorphism using PCR-RLFP. The mean serum levels of CCL20 in the MS group were significantly higher than in the healthy group (P < 0.001). In patients with a SPMS pattern, the frequency of CT genotype at rs6749704 (24.3 %) was significantly lower as compared to patients with other patterns (42.8 %; P < 0.04). No significant differences were observed between subjects with different genotypes in rs6749704 regarding the CCL20 levels. The mean serum levels of CCL20 in both newly diagnosed and previously diagnosed patients was significantly higher than in the healthy group (P < 0.05 and 0.001, respectively). The mean serum levels of CCL20 in patients with RRMS, SPMS and PPMS patterns were significantly higher than in the healthy group (P < 0.004, P < 0.04, and 0.05, respectively). The levels of CCL20 in untreated patients and in patients who received interferon-β, methylprednisolone or the combination of interferon-β plus methylprednisolone were higher as compared to the control group (P < 0.05, P < 0.03, P < 0.005, and P < 0.05, respectively). These results showed higher levels of CCL20 in patients that represent that the chemokine may play an important role in the pathogenesis of MS. The rs6749704 polymorphism was an associated SPMS pattern. The levels of CCL20 were not influenced by gender, disease pattern and treatment.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24395091     DOI: 10.1007/s12031-013-0214-2

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  25 in total

1.  Clinical study on CXCL13, CCL17, CCL20 and IL-17 as immune cell migration navigators in relapsing-remitting multiple sclerosis patients.

Authors:  Alicja Kalinowska-Łyszczarz; Adam Szczuciński; Mikołaj A Pawlak; Jacek Losy
Journal:  J Neurol Sci       Date:  2010-10-13       Impact factor: 3.181

Review 2.  Emerging new roles of Th17 cells.

Authors:  Vijay K Kuchroo; Amit Awasthi
Journal:  Eur J Immunol       Date:  2012-09       Impact factor: 5.532

Review 3.  Th17 cell, the new player of neuroinflammatory process in multiple sclerosis.

Authors:  F Jadidi-Niaragh; A Mirshafiey
Journal:  Scand J Immunol       Date:  2011-07       Impact factor: 3.487

Review 4.  Role of Th17 cells in the pathogenesis of CNS inflammatory demyelination.

Authors:  Abdolmohamad Rostami; Bogoljub Ciric
Journal:  J Neurol Sci       Date:  2013-04-08       Impact factor: 3.181

Review 5.  Cytokine control of inflammation and repair in the pathology of multiple sclerosis.

Authors:  Jane M Rodgers; Stephen D Miller
Journal:  Yale J Biol Med       Date:  2012-12-13

6.  Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.

Authors:  W I McDonald; A Compston; G Edan; D Goodkin; H P Hartung; F D Lublin; H F McFarland; D W Paty; C H Polman; S C Reingold; M Sandberg-Wollheim; W Sibley; A Thompson; S van den Noort; B Y Weinshenker; J S Wolinsky
Journal:  Ann Neurol       Date:  2001-07       Impact factor: 10.422

Review 7.  Role of regulatory T cells in pathogenesis and biological therapy of multiple sclerosis.

Authors:  Milan Buc
Journal:  Mediators Inflamm       Date:  2013-05-12       Impact factor: 4.711

8.  Systemic inflammation in progressive multiple sclerosis involves follicular T-helper, Th17- and activated B-cells and correlates with progression.

Authors:  Jeppe Romme Christensen; Lars Börnsen; Rikke Ratzer; Fredrik Piehl; Mohsen Khademi; Tomas Olsson; Per Soelberg Sørensen; Finn Sellebjerg
Journal:  PLoS One       Date:  2013-03-01       Impact factor: 3.240

9.  A one year follow-up study of natural killer and dendritic cells activities in multiple sclerosis patients receiving glatiramer acetate (GA).

Authors:  Rune A Høglund; Trygve Holmøy; Hanne F Harbo; Azzam A Maghazachi
Journal:  PLoS One       Date:  2013-04-22       Impact factor: 3.240

10.  CC Chemokine Ligand 20 and Its Cognate Receptor CCR6 in Mucosal T Cell Immunology and Inflammatory Bowel Disease: Odd Couple or Axis of Evil?

Authors:  Adrian Y S Lee; Rajaraman Eri; Alan B Lyons; Michael C Grimm; Heinrich Korner
Journal:  Front Immunol       Date:  2013-07-15       Impact factor: 7.561

View more
  20 in total

Review 1.  A comprehensive review on the role of chemokines in the pathogenesis of multiple sclerosis.

Authors:  Soudeh Ghafouri-Fard; Kasra Honarmand; Mohammad Taheri
Journal:  Metab Brain Dis       Date:  2021-01-06       Impact factor: 3.584

Review 2.  Genetic and Molecular Biology of Multiple Sclerosis Among Iranian Patients: An Overview.

Authors:  Meysam Moghbeli
Journal:  Cell Mol Neurobiol       Date:  2019-09-03       Impact factor: 5.046

3.  Genetic polymorphism patterns suggest a genetic driven inflammatory response as pathogenesis in appendicitis.

Authors:  Jan Dimberg; Marie Rubér; Marita Skarstedt; Manne Andersson; Roland E Andersson
Journal:  Int J Colorectal Dis       Date:  2019-12-16       Impact factor: 2.571

4.  CCL20 is elevated during obesity and differentially regulated by NF-κB subunits in pancreatic β-cells.

Authors:  Susan J Burke; Michael D Karlstad; Kellie M Regal; Tim E Sparer; Danhong Lu; Carrie M Elks; Ryan W Grant; Jacqueline M Stephens; David H Burk; J Jason Collier
Journal:  Biochim Biophys Acta       Date:  2015-04-13

5.  The Effects of IFN-β 1a on the Expression of Inflammasomes and Apoptosis-Associated Speck-Like Proteins in Multiple Sclerosis Patients.

Authors:  Saam Noroozi; Hossein Ali Ebrahimi Meimand; Mohammad Kazemi Arababadi; Nouzar Nakhaee; Gholamreza Asadikaram
Journal:  Mol Neurobiol       Date:  2016-03-31       Impact factor: 5.590

6.  Increased Concentrations of Interleukin-33 in the Serum and Cerebrospinal Fluid of Patients with Multiple Sclerosis.

Authors:  Abdollah Jafarzadeh; Roya Mahdavi; Mitra Jamali; Hossain Hajghani; Maryam Nemati; Hossain-Ali Ebrahimi
Journal:  Oman Med J       Date:  2016-01

7.  Altered Expression of Specific Transcription Factors of Th17 (RORγt, RORα) and Treg Lymphocytes (FOXP3) by Peripheral Blood Mononuclear Cells from Patients with Multiple Sclerosis.

Authors:  Zahra Etesam; Maryam Nemati; Mohammad-Amin Ebrahimizadeh; Hossain-Ali Ebrahimi; Hossain Hajghani; Tahereh Khalili; Razieyeh Frootan; Nahid Zinoddini; Abdollah Jafarzadeh
Journal:  J Mol Neurosci       Date:  2016-07-02       Impact factor: 3.444

8.  The dynamics of mucosal-associated invariant T cells in multiple sclerosis.

Authors:  Makoto Hirotani; Kazunori Yoshikiyo; Chie Sugimoto; Uichi Koshimizu; Rika Wakao; Takahiro Horinouchi; Yuichi Mazaki; Tsunehiko Higashi; Toshiyuki Fukazawa; Hiroyoshi Fujita; Hidenao Sasaki; Hiroshi Wakao
Journal:  Springerplus       Date:  2016-08-05

9.  The Relationship Between Chemokine and Chemokine Receptor Genes Polymorphisms and Chronic Obstructive Pulmonary Disease Susceptibility in Tatar Population from Russia: A Case Control Study.

Authors:  Gulnaz F Korytina; Yulia G Aznabaeva; Leysan Z Akhmadishina; Olga V Kochetova; Timur R Nasibullin; Naufal Sh Zagidullin; Shamil Z Zagidullin; Tatyana V Viktorova
Journal:  Biochem Genet       Date:  2021-06-06       Impact factor: 1.890

10.  Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months.

Authors:  Stefania De Mercanti; Simona Rolla; Angele Cucci; Valentina Bardina; Eleonora Cocco; Anton Vladic; Silva Soldo-Butkovic; Mario Habek; Ivan Adamec; Dana Horakova; Pietro Annovazzi; Francesco Novelli; Luca Durelli; Marinella Clerico
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2016-01-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.